Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087628 · ClinicalTrials.gov registry record · Phase 2
PRV-3279-2a Trial in Systemic Lupus
A Phase 2 study, sponsored by Provention Bio, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT05087628: Clinical Trial Phase 2 study, sponsored by Provention Bio, a Sanofi Company.
NCT05087628 is a Phase 2 study that was terminated before completion, run by Provention Bio, a Sanofi Company. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05087628, a Phase 2 study, was terminated before completion, sponsored by Provention Bio, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
Primary Outcome
Improvement in SLE disease activity:no lupus flare during baseline to Week 24. Lupus flare:Investigator's assessment that SLE activity met Lupus Foundation of America international consensus definition for flare (defined as measurable increase in disease activity in 1 or more organ systems involving new or worse clinical signs and symptoms and/or laboratory measurements,must be considered clinically significant by the assessor,and usually there would be at least consideration of a change or an i
Interventions
- OTHER Placebo
- BIOLOGICAL PRV-3279
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 2 |
Why NCT05087628 stopped before completion
NCT05087628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05087628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05087628 about?
NCT05087628 is a clinical study titled "PRV-3279-2a Trial in Systemic Lupus". The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
What is the current status of trial NCT05087628?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2022-01-20. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05087628?
The interventions under investigation include: Placebo (OTHER), PRV-3279 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05087628?
This trial is sponsored by Provention Bio, a Sanofi Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05087628's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI